scholarly article | Q13442814 |
P50 | author | Rainer Storb | Q19546769 |
Gitte Olesen | Q125345091 | ||
Brenda M Sandmaier | Q75025355 | ||
Marco Mielcarek | Q75025887 | ||
Paul J Martin | Q85264853 | ||
Michael A Pulsipher | Q87000372 | ||
Mary E D Flowers | Q87982223 | ||
Amelia A Langston | Q100756821 | ||
Ann E Woolfrey | Q114425570 | ||
P2093 | author name string | Barry E Storer | |
Michael B Maris | |||
David G Maloney | |||
Thomas R Chauncey | |||
Wolfgang A Bethge | |||
Jonathan A Gutman | |||
Brian Kornblit | |||
Fred R Appelbaum | |||
Soeren L Petersen | |||
P2860 | cites work | CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials | Q24614759 |
Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. | Q30252205 | ||
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens | Q33387336 | ||
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators | Q33594562 | ||
Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. | Q34077792 | ||
A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation | Q34272554 | ||
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation | Q35750957 | ||
Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis | Q35900978 | ||
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning | Q36007719 | ||
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis | Q36206849 | ||
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation | Q36662042 | ||
The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial | Q36734547 | ||
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation | Q36763834 | ||
The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate | Q36862464 | ||
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors | Q36926722 | ||
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantat | Q37238884 | ||
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation | Q37247581 | ||
The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. | Q37670062 | ||
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects | Q40706569 | ||
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation | Q44107506 | ||
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc | Q44189578 | ||
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies | Q44468881 | ||
Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation | Q46608663 | ||
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation | Q80001093 | ||
Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation | Q88068526 | ||
Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide | Q89642094 | ||
Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation | Q90356426 | ||
P433 | issue | 8 | |
P921 | main subject | sirolimus | Q32089 |
cyclosporine | Q367700 | ||
multicenter clinical trial | Q6934595 | ||
phase III clinical trial | Q42824827 | ||
P304 | page(s) | e409-e418 | |
P577 | publication date | 2019-06-24 | |
P1433 | published in | The Lancet. Haematology. | Q26840042 |
P1476 | title | Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial | |
P478 | volume | 6 |
Q103045571 | Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT |
Q89763444 | Does a pulmonary rehabilitation based ERAS program (PREP) affect pulmonary complication incidence, pulmonary function and quality of life after lung cancer surgery? Study protocol for a multicenter randomized controlled trial |
Q103805173 | Incorporation of posttransplant cyclophosphamide as part of standard immunoprophylaxis for all allogeneic transplants: a retrospective, single institution study |
Q91975895 | Sirolimus as Rescue Therapy for Refractory/Relapsed Immune Thrombocytopenia: Results of a Single-Center, Prospective, Single-Arm Study |
Q93086092 | Sirolimus-based graft-versus-host disease prophylaxis |
Search more.